Peer-Reviewed Publications

      Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses

      Poussin, C.; Titz, B.; Xiang, Y.; Baglia, L.; Berg, R.; Bornand, D.; Choukrallah, M. A.; Curran, T.; Dijon, S.; Dossin, E.; Dulize, R.; Etter, D.; Fatarova, M.; Felber Medlin, L.; Haiduc, A.; Kishazi, E.; Kolli, A. R.; Kondylis, A.; Kottelat, E.; Laszlo, C.; Lavrynenko, O.; Eb-Levadoux, Y.; Nury, C.; Peric, D.; Rizza, M.; Schneider, T.; Guedj, E.; Calvino, F.; Sierro, N.; Guy, P.; Ivanov, N. V.; Picavet, P.; Spinelli, S.; Hoeng, J.; Peitsch, M.C.

      Published
      Feb 21, 2024
      DOI
      10.1038/s41598-024-54474-2
      PMID
      38383592
      Link to publication
      Topic
      Summary

      Cigarette smoking is a major preventable cause of morbidity and mortality. While quitting smoking is the best option, switching from cigarettes to non-combustible alternatives (NCAs) such as e-vapor products is a viable harm reduction approach for smokers who would otherwise continue to smoke. A key challenge for the clinical assessment of NCAs is that self-reported product use can be unreliable, compromising the proper evaluation of their risk reduction potential. In this cross-sectional study of 205 healthy volunteers, we combined comprehensive exposure characterization with in-depth multi-omics profiling to compare effects across four study groups: cigarette smokers (CS), e-vapor users (EV), former smokers (FS), and never smokers (NS). Multi-omics analyses included metabolomics, transcriptomics, DNA methylomics, proteomics, and lipidomics. Comparison of the molecular effects between CS and NS recapitulated several previous observations, such as increased inflammatory markers in CS. Generally, FS and EV demonstrated intermediate molecular effects between the NS and CS groups. Stratification of the FS and EV by combustion exposure markers suggested that this position on the spectrum between CS and NS was partially driven by non-compliance/dual use. Overall, this study highlights the importance of in-depth exposure characterization before biological effect characterization for any NCA assessment study.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.